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ABSTRACT 
Drug use evaluation is an ongoing, systematic, criteria-based program of medicine evaluations that will help ensure appropriate medicine use. If 
therapy is determined to be inappropriate, interventions with providers or patients will be necessary to optimize pharmaceutical therapy. A 
DUE can be structured so that it will assess the actual process of administering or dispensing a medicine (i.e., appropriate indications, dose, and 
medicine interactions) or assess the outcomes. Empirical therapy forms the basis of treatment in India mostly and it is the responsibility of DTC 
(Drugs and therapeutics committee) to organize a DUE study and adopt suitable protocol for controlling irrational drug use. I n our study we 
have developed a data collection form based upon WHO guidelines for conducting a DUE study on piperacillin and tazobactum use evaluation. 
To assess the usage of piperacillin and tazobactum at a tertiary care center Hyderabad compared to the indications for piperacil lin and 
tazobactum use and standard treatment guidelines and provide recommendations to improve rational use of piperacillin and tazobactum at 
these hospitals and reduce the development of further antibiotic resistance, prevent ADRs associated with the drug, and to reduce the economic 
burden on the patient with inappropriate use. A retrospective evaluation of piperacillin and tazobactum usage patterns was carried out at a 
tertiary care hospital for the period of 3 months corresponding to the dates to 1-1-2018 to 31-3-2018. For conducting the evaluation process 
we had followed the standard guide lines formulated by WHO. The gender distributions of casesheets were male- 42, female- 23. Indication 
wise the distribution of case sheets were mostly treated for surgical prophylaxis, prophylaxis and infections. Out of 65 cases 65 (99%) has met 
the established criteria, they are as per STGs. Illness most frequently treated with piperacillin and tazobactum is ckd with acute deterioration 
(29.23%). The minimum number of days of treatment was 3 day and the maximum number of days of treatment was 14days.  All patient folders 
evaluated with regards to HD, SEPTIC SHOCK, PNEMOMEDIATINM etc were found to meet the standard criteria appropriate for piperacillin and 
tazobactum use with respect to dose, and dose frequency. However, in the case of dose duration the evaluation was found to be largely 
inappropriate for all the justified indications. In addition, 33.84% of piperacillin and tazobactum use for unjustified indications was noted. This 
means that piperacillin and tazobactum has been deviated from standard treatment guidelines hence it facilitates the development of resistant 
strains to piperacillin and tazobactum and of no use in the near future, and it also effect the patient economically. 
Keywords: DUE, piperacillin and tazobactum, WHO, tertiary care center, Hyderabad.  
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INTRODUCTION 
Drug use evaluation is an ongoing, systematic, criteria-based 
program of medicine evaluations that will help ensure 
appropriate medicine use. If therapy is determined to be 
inappropriate, interventions with providers or patients will 
be necessary to optimize pharmaceutical therapy. A DUE can 
be structured so that it will assess the actual process of 
administering or dispensing a medicine (i.e., appropriate 
indications, dose, medicine interactions) or assess the 
outcomes. The following eight steps outline the basic 
information necessary to start and maintain a DUE Program. 
Establish Responsibility: 
 Responsibility falls to the DTC or a subcommittee of the DTC 
that functions only to monitor DUEs In the hospital or clinic. 
The DTC should undertake this responsibility with 
considerable interest, because this process can solve many 
medicine use problems, as has proven to be the Case in many 
countries where this quality assurance function has been 
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fully utilized. The DTC or a subcommittee must establish 
procedures that will govern the committee in its activities 
concerning medicine use review and evaluation. As part of 
the responsibility of the DUE function, the DTC must 
establish a plan, outlining which medicines will be a part of 
the DUE process. This plan needs to be updated and 
evaluated each year. 
Develop Scope of Activities 
 The DTC should assess and identify medicine use problems 
and using this information to develop a scope of activity for 
the DUE program. The scope can be extensive, or it can focus 
on a single aspect of pharmaceutical therapy. Methods to 
identify medicine use problems include and ABC or vital, 
essential, nonessential (VEN) analysis, defined daily dose 
analysis, ADR reports, medication error reports, antibiotic 
sensitivity results, procurement studies, hospital and 
primary care clinic indicator studies, patient complaints or 
feedback, and staff feedback. These screening mechanisms 
serve to provide the DTC with information concerning 
medicine use that would need further evaluation in a DUE. 
Establish Criteria, Define and Establish Thresholds 
 Criteria are statements that define correct medicine use. 
Establishing criteria is the single most important procedure 
in a DUE. Criteria for the use of any medicine should be 
established by the DTC using relevant evidence based 
literature sources and recognized international and local 
experts. The criteria for any DUE should reflect what is in the 
country’s STGs (assuming that they have been developed 
correctly) and any medicine-use protocols that exist. 
Credibility of the DUE relies on criteria that are based on 
evidence-based medicine. Criteria must be developed with 
and accepted by the medical staff for the process to be 
credible. Criteria should be developed for three to five of the 
most important indicators for each aspect of medicine use. 
Reviewing larger numbers of indicators will make for a more 
difficult DUE process and may significantly impair the 
outcomes of the review. This is not to say that more 
extensive use of indicators should not be reviewed, only that 
results are more easily obtained and possibly more 
meaningful when the scope is narrowed to include only the 
most important aspects of care. After developing criteria, the 
DTC must establish a threshold or standard (benchmark) 
against which the criteria will be judged. A threshold refers 
to the percentage of charts or records that will meet or 
exceed the established criteria for the medicine. Ideally, this 
threshold will be 100 percent, but realistically, a smaller 
percentage will be more appropriate to account for 
exceptions to routine medicine prescribing. Therefore, a 
threshold of 90 to 95 percent is typically used for many 
criteria, but each instance must be carefully analyzed before 
reaching a conclusion. 
Collect Data and Organize Results. 
 DUEs can be accomplished as prospective evaluations, or 
they can be performed retrospectively. A prospective 
analysis involves the collection of data as the medicine is 
being prepared or dispensed to the patient. Retrospective 
analysis is done using chart reviews or other data sources to 
review medicine use according to indicators and criteria 
prepared in advance. The advantage of a prospective review 
is that the pharmacist (or other reviewer) can intervene at 
the time the medicine is dispensed to prevent errors in, for 
example, dosage, indications, or interactions. Retrospective 
evaluation, which may involve more of the reviewer’s time or 
require access to medical records, is best accomplished when 
the reviewer has time away from the patient care areas and 
distractions. 
Analyze Data  
Data are collected, tabulated, and analyzed to see if criteria 
and thresholds are met. The following important steps 
should be completed when analyzing data— 
• Tabulate results for each indicator 
• Analyze results to see if the criteria are met and the 
thresholds are not exceeded 
• Determine why thresholds are not met 
• Analyze data quarterly or more frequently 
If a threshold is not met, it may indicate a medicine use 
problem that requires the attention of the DTC. 
Develop Recommendations and Action Plan  
After completing the data analysis, information is presented 
to the DTC and a decision is made as to the appropriateness 
of the information in the DUE. The DTC also must decide on 
whether to continue, discontinue, or expand the functions of 
the DUE in question. All medicines that do not meet the 
thresholds must be evaluated carefully and plans must be 
made to improve the use of the medicine relative to the 
criteria. 
Recommendations should be prepared for the DTC to 
address the following— 
• Inappropriate medicine use 
• Unacceptable patient outcomes 
• Methods to resolve any medicine use problem 
Recommendations should include specific steps to correct 
any medicine use problem that is evident from performing 
the DUE. For example, if a specific medicine is being 
prescribed at a high dose, then the recommendations need to 
reflect this and how the DTC might improve the dosing of 
this medicine. Interventions to improve medicine use might 
include— 
• Education, including letters to practitioners, in-service 
education, workshops, newsletters, and face to-face 
discussions 
• Implementation of medicine order forms 
• Prescribing restrictions 
• Formulary manual changes 
• Change (or better enforcement) of the STGs. 
Conduct DUE Follow-up  
Follow-up in every DUE is critical to ensure resolution of any 
unresolved medicine use problems. The DUE may have 
identified new problems that need to be resolved within the 
health care system. If the problems are not resolved, then the 
DUE will have little usefulness to the health care system. As a 
part of a follow-up plan, the DTC must assess the need to 
continue, modify, or stop the DUE activity depending on the 
results of each specific medicine review. A DUE should be an 
ongoing process in which medicine related problems are 
regularly addressed. Medicine review should be considered a 
long-term program, one that is continuously updated and 
revised to reflect current situations and needs within the 
health care institution. All programs within the DTC should 
be evaluated yearly. This complete evaluation is necessary to 
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look comprehensively at the entire program and analyze its 
merits and its utility in improving medicine use. Programs 
that do not have a significant impact on medicine use should 
be redesigned so that they can provide measurable 
improvements. Without improvements in medicine use and 
patient outcomes, the time spent on DUE will be of no value. 
It must be stressed that indicators and criteria for a DUE can 
be highly individualized depending on the specific needs of 
the health care facility.[1,2] 
Piperacillin and tazobactam for injection: 
Piperacillin sodium exerts bactericidal activity by inhibiting 
septum formation and cell wall synthesis of susceptible 
bacteria. In vitro, piperacillin is active against a variety of 
gram-positive and gram-negative aerobic and anaerobic 
bacteria. Tazobactam sodium has little clinically relevant in 
vitro activity against bacteria due to its reduced affinity to 
penicillin-binding proteins. It is, however, a β-lactamase 
inhibitor of the Richmond-Sykes class III (Bush class 2b & 
2b') penicillinases and cephalosporinases. It varies in its 
ability to inhibit class II and IV (2a & 4) penicillinases. 
Tazobactam does not induce chromosomally-mediated β-
lactamases at tazobactam concentrations achieved with the 
recommended dosage regimen. 
Piperacillin and Tazobactam for injection, USP) is indicated 
for the treatment of patients with moderate to severe 
infections caused by piperacillin-resistant, 
piperacillin/tazobactamsusceptible, β-lactamase producing 
strains of the designated microorganisms in the specified 
conditions- Appendicitis (complicated by rupture or abscess) 
and peritonitis caused by piperacillin-resistant, β-lactamase 
producing strains of Escherichia coli or the following 
members of the Bacteroides fragilis group: B. fragilis, B. 
ovatus, B. thetaiotaomicron, or B. vulgatus. The individual 
members of this group were studied in less than 10 cases. 
Uncomplicated and complicated skin and skin structure 
infections, including cellulitis, cutaneous abscesses, and 
ischemic/diabetic foot infections caused by piperacillin-
resistant, β-lactamase producing strains of Staphylococcus 
aureus. Postpartum endometritis or pelvic inflammatory 
disease caused by piperacillin-resistant, βlactamase 
producing strains of Escherichia coli. Community-acquired 
pneumonia (moderate severity only) caused by piperacillin-
resistant, βlactamase producing strains of Haemophilus 
influenzae. Nosocomial pneumonia (moderate to severe) 
caused by piperacillin-resistant, β-lactamase producing 
strains of Staphylococcus aureus and by 
piperacillin/tazobactam-susceptible Acinetobacter baumanii, 
Haemophilus influenzae, Klebsiella pneumoniae, and 
Pseudomonas aeruginosa (Nosocomial pneumonia caused by 
P. aeruginosa should be treated in combination with an 
aminoglycoside). Piperacillin and Tazobactam for injection is 
indicated only for the specified conditions listed above. 
Infections caused by piperacillin-susceptible organisms, for 
which piperacillin has been shown to be effective, are also 
amenable to Piperacillin and Tazobactum treatment due to 
its piperacillin content. The tazobactam component of this 
combination product does not decrease the activity of the 
piperacillin component against piperacillin-susceptible 
organisms. Therefore, the treatment of mixed infections 
caused by piperacillin-susceptible organisms and piperacillin 
resistant, β-lactamase producing organisms susceptible to  
piperacillin and Tazobactun should not require the addition 
of another antibiotic. Piperacillin and Tazobactum is useful 
as presumptive therapy in the indicated conditions prior to 
the identification of causative organisms because of its broad 
spectrum of bactericidal activity against gram-positive and 
gram-negative aerobic and anaerobic organisms. 
Appropriate cultures should usually be performed before 
initiating antimicrobial treatment in order to isolate and 
identify the organisms causing infection and to determine 
their susceptibility to Piperacillin and Tazobactum. 
Antimicrobial therapy should be adjusted, if appropriate, 
once the results of culture(s) and antimicrobial susceptibility 
testing are known. To reduce the development of drug-
resistant bacteria and maintain the effectiveness of 
piperacillin and tazobactam injection and other antibacterial 
drugs, piperacillin and tazobactam should be used only to 
treat or prevent infections that are proven or strongly 
suspected to be caused by susceptible bacteria. When culture 
and susceptibility information are available, they should be 
considered in selecting or modifying antibacterial therapy. In 
the absence of such data, local epidemiology and 
susceptibility patterns may contribute to the empiric 
selection of therapy.[3] 
Aim: 
 To assess the usage of piperacillin and tazobactum at a 
tertiary care center in Hyderabad compared to the 
indications for piperacillin and tazobactum use and standard 
treatment guidelines and provide recommendations to 
improve rational use of piperacillin and tazobactum at these 
hospitals and reduce the development of further antibiotic 
resistance, prevent ADRs associated with the drug, and to 
reduce the economic burden on the patient with 
inappropriate use.  
Objective:  
 To analyse the pattern of piperacillin and tazobactum 
use among patient categories identified by age.  
 To identify the illnesses most frequently treated with 
piperacillin and tazobactum. 
 To determine whether piperacillin and tazobactum was 
appropriately prescribed in respect of dose, dose fre-
quency, and dose duration.  
 To identify areas in which further information and 
education was needed by health care provider.  
 To evaluate reason for stopping (discontinue) the drug 
is based on guide line or not.  
 To assess whether the indication of piperacillin and 
tazobactum is on par with standard guidelines or not. 
 To assess the frequency of ADRs associated with the 
drug use. 
 To assess the potential and actual Drug-Drug 
interactions associated with piperacillin and 
tazobactum. 
MATERIALS AND METHODS 
 Study Design: Retrospective Drug Utilization Evaluation 
Study. 
Study Site: A tertiary Care Center at Hyderabad, India. 
Study Duration: 3 months. 
Source of Data: A Data-collection form was developed based 
on WHO Guidelines. 
Sample Size: 65.  
Study Procedure: Since it is a retrospective study, we have 
collected all the case records from the medical record 
department from 1-01-2018 to 31-3-2018 that contained 
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piperacillin and tazobactum in the prescription. A total of 65 
case records were obtained containing piperacillin and 
tazobactum as a drug in the prescription. During the process 
of evaluation, the prescriptions were analyzed for correct 
indication, correct dose, frequency, ADRs, Drug-Drug 
interactions, and contra-indications. The criterion 
established was adopted from standard treatment guidelines 
as formulated by FDA.  The Threshold was developed by 
taking into consideration, the prescribing habits (KAP) of the 
doctors at these centers, the indicators are assigned with a 
threshold of 90-100%. 
Statistical analysis:  Descriptive statistical analysis has been 
carried out in the present study where ever necessary. 
RESULTS 
A total of 65 case sheets were obtained that contained 
piperacillin and tazobactum as one of the drug in the 
treatment plan during the course of their stay at hospital. 
The 65number of cases were obtained from the following 
dates: 1-1-18 to 31-3-18. Month wise the number of case 
sheets that contained piperacillin and tazobactum are as 
follows:
 
months nephrology gynecology pediatrics gastroenterology pulmonology total 
Jan  24 2 3 3 1 33 
feb 13 2 2 1 2 20 
march 8 1 2 1 0 12 
 
Percentage of Piperacillin and Tazobactum usage in 
each department:   
Department:  
Nephrology -45 
Paediatrics-7 
Gastroenterology-5 
Gynecology-5 
Pulmonology -3  
Total overall cases reviewed are 65 case sheets. 
Age wise the number of case sheets that contain piperacillin 
and tazobactum are as follows: 
AGE GROUP No. OF CASES 
0-10 4 
11-20 4 
21-30 7 
31-40 14 
41-50 8 
51-60 21 
61-70 5 
71-80 0 
81-90 2 
91-100 0 
  
Gender wise the number of case sheets that contain 
piperacillin and tazobactum are as follows: 
Males = 42 
Female = 23 
Indication wise number of case sheets that contain 
piperacillin and tazobactum areas follows: 
Nephrology indications: 
Hemodialysis – 12 
PCN -1 
Obstructive uropathy – 3 
Ckd – acute deterioration – 19 
AKI – 10 
Pediatrics: 
Blunt injury with pneunomediastinum – 1 
Endotracheal tube – 1 
Preoperative prophylaxis, of biliary tree surgery – 1 
Central venous catheter with fever – recent abdominal 
surgery -1 
Tracheitis -1 
Nasocomial pneumonia -1 
Post operative purulent wounds -1 
Gynecology: 
Pelvic peritonitis -1 
Bartollins abscess -1 
Abdominal hysterectomy -1 
UTI -1 
Acute salpingitis -1 
Gastroenterology: 
Foleys catheter -1 
EVL -1 
Biliary Stent Removed, Hilar Stricture -1 
Post adjunct chemotherapy -1 
Acute cholangitis -1 
Pulmonology: 
Rt – synpneumonic effusion, CAP, kochs -2 
Pulmonary hypertension -1 
 Age v/s duration of piperacillin and tazobactum therapy is 
as follows: 
Age Min(days) Max(days) 
0-10 1 7 
11-20 1 19 
21-30 3 14 
31-40 1 19 
41-50 3 19 
51-60 1 15 
61-70 3 18 
71-80 0 0 
81-90 4 5 
91-100 0 0 
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Dose per Day: 
The minimum dose used per day is 1.5 g and maximum dose 
used per day is 5 g. 
DISCUSSION 
Piperacillin/tazobactam, sold under the brand names piptaz 
among others, is a combination medication containing the 
antibiotic piperacillin and the β-lactamase inhibitor 
tazobactam. The combination has activity against many 
Gram-positive and Gram-negative bacteria including 
Pseudomonas aeruginosa.The development of resistance by 
microorganisms is of global concern. This is because 
microorganisms that were susceptible to some anti-infective 
agents have now become resistant. Unfortunately, irrational 
prescribing is a global problem. Studies on medicine 
prescribing in India have concluded that much of it is 
irrational. Making a prescribing decision is vital in the 
prevention of morbidity and mortality. The physician’s 
prescribing decision is the result of input from patients, 
commercial sources, professional colleagues, academic 
literature, and government regulations. Ineffective use of 
these sources of information can result in a wide variety of 
prescribing errors. Medicine utilization review is the most 
common and structured approach used to examine patterns 
of medicine use and to determine levels of appropriateness 
in prescribing. Medicine usage reviews are essential to 
establish the extent of rational and irrational prescribing 
and to deliver better healthcare services. Antimicrobials, like 
any other medicines, may be used inappropriately. A 
prescriber may choose an inappropriate type of 
antimicrobial, taking into account the clinical condition, 
resistance patterns and cost. Continuing antimicrobial 
misuse leads not only to poor patient outcome, unnecessary 
adverse reactions and wasted resources, but also to 
emerging resistance of bacteria to antimicrobials. 
Antimicrobials can also be very expensive, and in most 
facilities, they constitute a major portion of the drug budget. 
The phenomenon of resistance is seen not only in bacteria 
and mycobacterium (multidrug resistant TB, for example), 
but also in protozoal infections (resistance to chloroquine as 
an antimalarial) and viral infections (HIV and 
antiretroviral).This study provides the data on the use of 
piperacillin and tazobacum at a tertiary care centre in 
hyderabad. The considered parameters are age, gender, 
indication, dose, frequency, duration of therapy, 
contraindications and drug interacting with piperacillin and 
tazobactum. 
1. Drug utilization pattern according to gender: 
A total of 65 cases of piperacillin and tazobactum use were 
identified between the period from 1/1/18 - 31/3/18 
patient. The distribution of cases on gender basis is   males 
(35.38%) and females (64.61%).  
2. Drug utilization pattern according to age: 
The age range was between 5yrs to 85yrs. The usage pattern 
of piperacillin and tazobactum among various age groups 
are as follows:  of 0-10 (6.15%), 11-20 (6.15%),    21-30yrs 
(10.76%) and 31-40 (21.53%), 41-50 (12.30%), 51-60 
(32.30%), 61-70 (7.69%), 71-80 (0%), 81-90 (3.07%) and   
91-100 (0%). As per STGs, the percentage of piperacillin and 
tazobactum used among the age group 0-10 years hasn’t met 
the established criteria, and the rest met the criteria. 
 3. Drug utilization pattern according to indication: 
In our study, the percentage of piperacillin and tazobactum 
indicated in the conditions    are:- 
Nephrology indications: 
Hemodialysis – 12(18.46%) 
 PCN -1(1.53%) 
 Obstructive uropathy – 3(4.61%) 
 Ckd – acute deterioration – 19(29.23%) 
 AKI – 10(15.38%) 
Pediatrics: 
 Blunt injury with pneunomediastinum – 1(1.53%) 
 Endotracheal tube – 1(1.53%) 
 Preoperative prophylaxis, of biliary tree surgery – 
1(1.53%) 
 Centralvenous catheter with fever – recent abdominal 
surgery -1(1.53%) 
 Tracheitis -1(1.53%) 
 Nasocomial pneumonia -1(1.53%) 
 Post operative purulent wounds -1(1.53%) 
Gynecology:  
 Pelvic peritonitis -1(1.53%) 
 Bartollins abscess -1(1.53%) 
 Abdominal hysterectomy -1(1.53%) 
 UTI -1(1.53%) 
 Acute salpingitis -1(1.53%) 
Gastroenterology: 
 Foleys catheter -1(1.53%) 
 EVL -1(1.53%) 
 Biliary Stent Removed, Hilar Stricture -1(1.53%) 
 Post adjunct chemotherapy -1(1.53%) 
 Acute cholangitis -1(1.53%) 
Pulmonology: 
 RT – synpneumonic effusion, CAP, kochs -2(1.53%) 
 Pulmonary hypertension -1(1.53%) 
Out of 65 cases 65 (99%) has met the established criteria, 
they are as per STGs. Illness most frequently treated with 
piperacillin and tazobactum is ckd with acute deterioration 
(29.23%)   Drug utilization pattern according to dose, 
ROA, Frequency, and the potential for interaction Drug 
utilization pattern according to dose, ROA, Frequency, 
and the potential for interaction In this research, the 
criteria of appropriateness of piperacillin and tazobactum 
use at the dose, dose frequency, dose duration were 
The dose of piperacillin and tazobactum based on indication 
and duration given was in all the indications studied, they 
met the benchmark requirement of 95%. Therefore 
piperacillin and tazobactum was used appropriately so far as 
dose was concerned. 
Out of 65 cases, dose frequencies were eight hours and 24 
hours in 6cases (9.23%) and 59cases (90.76%) respectively. 
Dose durations were mostly inappropriate for all the 
justified indications studied. According to STGs for 
Jagarlamudi et al                                                                                                 Journal of Drug Delivery & Therapeutics. 2019; 9(3):286-291 
ISSN: 2250-1177                                                                                  [291]                                                                                 CODEN (USA): JDDTAO 
hemodialysis patients average duration of therapy is 7 to 14 
days, results showed minimum of three days and maximum 
of fourteen days were given, on an average the results are 
appropriately meeting the STGs (100%). As per standards, 
the duration of piperacillin and tazobactum in hemodialysis 
is given for nineteen days hence duration of therapy fails to 
meet the standards. There would be a lot of carriers in the 
system and the disease would continue to be transmitted 
from person to person. Hence, it facilitates the development 
of resistant strains to piperacillin and tazobactum.  
Drug interactions The potential for piperacillin and 
tazobactum interaction with microlide antibiotics .Out of 
65cases (100%), cases (87.69%) are reported without any 
potential interaction and cases (9.93%) reported with 
interaction.  
Drugs interacting with piperacillin/tazobactam are: 
no interactions 87.69% 
doxycycline 3.01% 
azithromycin 3.46% 
clarithromycin 3.46% 
 
Culture sensitivity test:  
Nephrology 1case 
Pulmonolgy 2cases 
Gastroenterology 3cases 
Gynecology 1case 
Paediatrics 0 
without culture test 58cases 
 
Drug utilization pattern according to contraindication: 
In our study, out of 65 cases, all cases met the threshold of 
100% as per STG’s. 
Outcomes: 89% drug is given without culture test. Dose, 
duration as per STG’s.patients improved symptomatically 
and infection resolved almost cases. 33.84% are non 
indicated. 
Piperacillin and tazobactum duration of therapy 
thresholds measured: 
 
CONCLUSIONS AND RECOMMENDATION  
CONCLUSION 
All patient folders evaluated with regards to HD, SEPTIC 
SHOCK, PNEMOMEDIATINM etc were found to meet the 
standard criteria appropriate for piperacillin and 
tazobactum use with respect to dose, and dose frequency. 
However, in the case of dose duration the evaluation was 
found to be largely inappropriate for all the justified 
indications. In addition, 33.84% of piperacillin and 
tazobactum use for unjustified indications was noted. This 
means that piperacillin and tazobactum has been deviated 
from standard treatment guidelines hence it facilitates the 
development of resistant strains to piperacillin and 
tazobactum and of no use in the near future, and it also effect 
the patient economically. 
RECOMMENDATION: Health care providers must be 
periodically updated with the national standard treatment 
guidelines. It is further recommended that the hospital’s 
management attention be drawn to the draw backs observed 
regarding the inappropriate use and duration of piperacillin 
and tazobactum, so that specific interventions could be 
initiated to improve its use for excellent outcomes. 
Following the implementation of the interventions, another 
DUE should be conducted to determine the level of 
adherence to the acceptable standards and its impact on 
patient outcomes. 
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ABBREVIATIONS USED  
DTC –   Drug therapeutic committee 
DUE –   Drug utilization evaluation 
DUR –   Drug utilization Review 
FDA –   Food drug administration 
DDD –   Defined daily dose 
ADR–   Adverse drug reactions 
 PCN- Percutaneous nephrotomy 
 CKD- chronic kidney disease 
AKI- Acute kidney injury 
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